Q
QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

24,158 signal articles · 313 in last 24h · 114,663 total before filter · latest 12m ago
313last 24h
1910last 7d
299● bullish (7d)
166● bearish (7d)
205publishers
AllMacro327Earnings962M&A100Regulatory23Product17Analyst24
✕ clear all filtersticker: ^GSPCSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Morgan Stanley's Amazon earnings verdict has a blind spot
TheStreet12d agoneutral
Morgan Stanley's Amazon earnings verdict has a blind spot

Amazon (AMZN) stock closed the July 31 trading session up 15.32% at $271.58, as it soared following the release of its second quarter (Q2) 2026 earnings report on July 30. The stock is up 17.66% year-to-date as of Saturday morning, August 1. Meanwhile, the SPDR S&P 500 index (SPY) is up about ...

3 Reasons WMG is Risky and 1 Stock to Buy Instead
StockStory13d agobullish
3 Reasons WMG is Risky and 1 Stock to Buy Instead

Warner Music Group currently trades at $29.22 per share and has shown little upside over the past six months, posting a small loss of 2.6%. The stock also fell short of the S&P 500’s 7.1% gain during that period.

Citi Says Investor Positioning Remains Resilient Despite Signs of Weakening Beneath the Surface
InvestorsHub13d agoneutral
Citi Says Investor Positioning Remains Resilient Despite Signs of Weakening Beneath the Surface

Global investor positioning continues to reflect a generally positive outlook, although underlying strength is becoming increasingly concentrated in a smaller number of markets and sectors, according to Citi strategists. The bank said recent market activity suggests investors remain constructive overall, but divergences across regions and asset classes indicate that risks are beginning to build beneath the surface.

PepsiCo (PEP): Buy, Sell, or Hold Post Q2 Earnings?
StockStory13d agoneutral
PepsiCo (PEP): Buy, Sell, or Hold Post Q2 Earnings?

Over the past six months, PepsiCo’s shares (currently trading at $144.08) have posted a disappointing 6.2% loss, well below the S&P 500’s 7.1% gain. This may have investors wondering how to approach the situation.

2 Reasons to Like FAST (and 1 Not So Much)
StockStory13d agoneutral
2 Reasons to Like FAST (and 1 Not So Much)

Fastenal has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 10.9% to $48.10 per share while the index has gained 7.1%.

Investing.com13d agoneutral
CTA Nasdaq de-risking appears largely complete: BofA

Investing.com -- Commodity trading advisers have largely unwound their Nasdaq-100 exposure, with the index’s short-term trend strength falling to just 13% against 53% for the S&P 500, BofA Securities said in a recent note.

Ralph Lauren (RL) Gains Ahead Of Earnings As Fair Value Stays In Focus
Simply Wall St.13d agoneutral
Ralph Lauren (RL) Gains Ahead Of Earnings As Fair Value Stays In Focus

What triggered the latest focus on Ralph Lauren stock Ralph Lauren (RL) is back in focus after its stock outpaced the S&P 500 with a 2.72% gain on a recent trading day, ahead of an earnings release scheduled for August 6, 2026. This price move comes as the company prepares to report quarterly results that are expected to show higher earnings and revenue compared with the prior year, while analyst consensus on earnings has seen slight downward revisions. See our latest analysis for Ralph...

CRISPR Therapeutics (CRSP) Rebounded In Its Latest Session, Is It Still Well Below Fair Value?
Simply Wall St.13d agoneutral
CRISPR Therapeutics (CRSP) Rebounded In Its Latest Session, Is It Still Well Below Fair Value?

CRISPR Therapeutics Stock Reaction To Recent Trading Session CRISPR Therapeutics (NasdaqGM:CRSP) recently finished a trading session with a positive price move that outpaced the S&P 500. The stock is drawing attention as investors look ahead to its upcoming earnings report. See our latest analysis for CRISPR Therapeutics. At a share price of US$47.99, CRISPR Therapeutics has seen short term momentum cool, with a 30 day share price return down 13.72% and a 1 year total shareholder return down...

NVR (NVR): Buy, Sell, or Hold Post Q2 Earnings?
StockStory13d agoneutral
NVR (NVR): Buy, Sell, or Hold Post Q2 Earnings?

Over the past six months, NVR’s shares (currently trading at $6,296) have posted a disappointing 18.4% loss, well below the S&P 500’s 4.9% gain. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.